Yvonne Diaz, Director of Global Media Relations and Social Media at EY and Co-Founder of Oncogene Cancer Research, shared a post on X:
“MTAP loss feels like one of those biomarkers quietly sitting in the blind spot of Lung Cancer.
Dr Natasha Leighl’s ESMO25 presentation shows its potential not only in patients without known drivers, but also in those with co-occurring EGFR or ALK alterations — a space to watch.”
